Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Cystic Fibrosis Symptoms Improve with Ataluren

July 20, 2011 11:50 am | News | Comments

The three-month data from a Phase 2 study showed that treatment of adults with nonsense mutation cystic fibrosis (nmCF) with PTC Therapeutics Inc.’s ataluren resulted in improvements in chloride channel activity, CF-related cough, and positive trends in lung function.


Davunetide Performs Well in Early Schizophrenia Trial

July 20, 2011 8:07 am | News | Comments

Allon Therapeutics Inc. announced findings that 12 weeks of treatment with its lead product davunetide appears to prevent cortical thinning of important parts of the brains of schizophrenia patients.



July 20, 2011 7:48 am | Product Releases | Comments

QIAGEN launches the Multiplex PCR Plus Kit, designed for rapid and sensitive multiplex PCR that allows researchers to amplify several targets in one PCR run.


Online Plate Selector

July 20, 2011 7:46 am | Product Releases | Comments

Thermo Fisher Scientific Inc. announced its Nunc online plate selector guide, a tool for users to select the correct plate format for their applications. Choosing the right plate surface can optimize resulting data while increasing lab efficiency.


Malvern, Paraytec Sign Rights Agreement

July 20, 2011 7:41 am | News | Comments

Malvern Instruments Ltd and Paraytec Ltd have entered into a development and licensing agreement that will see Paraytec’s ActiPix technology being added to Malvern’s materials characterization portfolio.


Streamlining Innovation: The Role of In-silico Techniques

July 20, 2011 7:37 am | by Michael Doyle, PhD, Director of Product Marketing and Principal Scientist; Accelrys, Inc., San Diego, Calif. | Articles | Comments

There are few drug companies who haven’t experienced the pain of dumping millions of dollars and years of research into a compound that ultimately isn’t viable.


Talon Submits Marqibo NDA

July 20, 2011 7:11 am | News | Comments

Talon Therapeutics, Inc. announced the submission of a New Drug Application for Marqibo to the FDA. Talon is seeking accelerated approval of Marqibo in adult Ph- ALL, in second or greater relapse.


Pfizer to Acquire Icagen

July 20, 2011 6:58 am | by Linda A. Johnson | News | Comments

Pfizer Inc. says it's reached a definitive agreement to buy Icagen, a small biopharmaceutical company that specializes in developing pain treatments. The deal could boost Pfizer's portfolio in one of its priority research areas.


Abbott Profits Up Almost 50%

July 20, 2011 6:54 am | News | Comments

Drug and medical device maker Abbott Laboratories reported a 48 percent jump in its second-quarter profit on lower expenses and a one-time tax benefit.


FDA Panel Votes Against Diabetes Pill

July 20, 2011 6:47 am | by Matthew Perrone | News | Comments

The majority of advisers on a federal health panel say a first-of-a-kind diabetes drug that uses a new method to reduce blood sugar shouldn't be approved for U.S. patients after higher rates of bladder and breast cancer were reported.


Sterile Sampling System

July 19, 2011 12:45 pm | Product Releases | Comments

EMD Millipore’s NovaSeptum 60 mL bottle allows for the measurement of larger sample sizes than currently available syringe configurations. The sterile, closed, disposable system is used for sterile sampling of manufacturing processes.

P2D Bioscience Receives NIH Funding

July 19, 2011 12:26 pm | News | Comments

P2D Bioscience announced that the company has received a $320,000 grant from the U.S. National Heart, Lung and Blood Institute.


FDA Approves Vaccines for Upcoming Influenza Season

July 19, 2011 12:18 pm | News | Comments

The U.S. Food and Drug Administration (FDA) has approved the 2011-2012 influenza vaccine formulation for all six manufacturers licensed to produce and distribute influenza vaccine across the United States.


Daiichi Sankyo Launches Lixiana

July 19, 2011 12:13 pm | News | Comments

Daiichi Sankyo announced the launch of Lixiana (edoxaban) in Japan, which follows the first marketing approval for edoxaban 15 mg and 3 mg tablets by the Japanese Ministry of Health, Labor and Welfare in April 2011, and marks the first time edoxaban is commercially available to patients in any global market.


Lilly Follows Up on Halted Semagacestat Trial

July 19, 2011 12:08 pm | News | Comments

Eli Lilly and Company presented sata was presented from the first of two Phase III trials of semagacestat, including data from a 32 week follow-up period after dosing was halted in August 2010.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.